Taro, a subsidiary of Sun Pharma , showed good growth in
January-March quarter of 2012 on year-on-year basis, but there was dip in
margins sequentially.
Net income of Taro jumped 84% over a year ago period to USD
47.3 million for the fourth quarter of FY12. It has changed financial year to
March as against December.
Sales increased 34.7% to USD 145 million during the same
period.
Operating income went up 98% year-on-year to USD 66.2
million in the quarter ended March 2012. Operating margins too improved quite
nicely at 45.6% as against 31% year-on-year, but it declined as compared to
50.2% in previous quarter.
Cash flow from operations during the quarter stood at USD 78
million as against USD 24,4 million YoY.
Cash including marketable securities increased USD 75.5
million to USD 334.4 million sequentially.
Taro also posted excellent results in December quarter; net
sales grew by 44%YoY to USD 148.1 million in October-December quarter and
EBITDA margin improved from 21.1% to 50.2%.
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment